<DOC>
	<DOCNO>NCT02581995</DOCNO>
	<brief_summary>To evaluate change quality life ( NEI VFQ 25 ) subject DME first year treatment aflibercept accord EU Label .</brief_summary>
	<brief_title>Investigation Change Vision-related Quality Life Subjects Treated With Aflibercept According EU Label DME .</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<criteria>Type 1 2 diabetes mellitus Diagnosis DME secondary diabetes mellitus involve center macula ( defined area center subfield OCT ) study eye Decrease vision determine primarily result DME study eye BCVA study eye ETDRS letter score 73 24 ( This correspond Snellen equivalent approximately 20/40 20/320 . ) Pregnancy lactation Mismatch inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetic macular edema</keyword>
	<keyword>Intravitreal injection</keyword>
</DOC>